FUJIFILM, a provider of diagnostic imaging and medical informatics solutions, has announced that its ASPIRE Cristalle mammography system with digital breast tomosynthesis (DBT) now offers ScreenPoint Medical’s new, FDA cleared Transpara powered by Fusion AI for 2D and 3D mammography in the United States. ScreenPoint Medical’s AI solution, coupled with the ASPIRE Cristalle mammography system, displays breast screening findings at a doctor’s reading workstation or PACS system.
Building on a successful partnership with ScreenPoint Medical, Fujifilm’s customers using ASPIRE Cristalle with DBT now have access to ScreenPoint’s latest version of Transpara, an AI solution designed to help radiologists improve reading accuracy, readuce reading time, and improve workflow. Transpara includes three unique and competitive applications to help clinicians find cancerous lesions:
- Transpara Perception Aid: Findings that Transpara detects can be directly marked for review within the workstation, reducing the risk of overlooking significant abnormalities
- Transpara Decision Support: Allows radiologists to query any suspicious regions while reading mammograms.
- Transpara Score: Categorizes mammograms in ten equally sized groups, to present an increasing proportion of those with cancer. Most mammograms with cancer fall into the highest category (Transpara Score 10), while very few exams with cancerous lesions have a low score. The score’s display alerts radiologists to mammograms with a higher likelihood of cancer, while providing them with increased confidence for reporting normal exams.
“It’s critical that the healthcare industry continues to strive for early detection of lesions to reduce breast cancer mortality rates,” said Christine Murray, Women’s Health Product Manager, FUJIFILM Medical Systems U.S.A., Inc. “Fujifilm is thrilled to form and expand partnerships with leading companies that share the same commitment to improve patient lives through advances in breast imaging technology. By collaborating with ScreenPoint Medical, we are offering our customers the latest, intelligent clinical decision-support tools they need to improve mammography quality and identify potential breast cancers faster and earlier than before.”
More than 270,000 women are diagnosed with breast cancer every year in the United States, and more than 40,000 women will die from the disease over the same period. Diagnosis at an early stage due to routine screenings, represents one of the most important prognostic factors for survival. New studies find that the use of AI in breast cancer screening could reduce the workload of radiologists by up to 70%, without reducing cancer detection. Additionally, ScreenPoint Medical’s latest clinical studies of its AI solution have confirmed major new benefits for radiologists and their patients, including up to 35% of exams with interval cancers found on earlier mammograms, up to 70% of exams can now be confidently labelled as most likely normal to help reduce workload for increasingly pressured radiologists, improve efficiency and more.
“Consistent mammography quality and accuracy are critical to ensuring women get the best possible breast healthcare,” said Nico Karssemeijer, CEO of ScreenPoint Medical. “ScreenPoint Medical’s advanced AI-based solutions, coupled with a state of the art mammography system like the Fujifilm ASPIRE Cristalle, provide a powerful combination to help radiologists identify potential cancers faster and at an earlier stage to increase the chances of more women surviving breast cancer.”